As the parent ligands were inactive, this study identifies the important role of Pd(II) centre in phosphodiesterase
inhibition by Pd(II) complexes.
An oral, twice-daily, small-molecule phosphodiesterase
4 (PDE4) inhibitor that is FDA approved for the treatment of psoriasis, apremilast has inhibited TNF-[alpha], IL-12, and IL-23 in an in vitro model of psoriasis.
In patients who need both alpha-blockers and phosphodiesterase
inhibitors, I think tamsulosin is the safest alpha-blocker option.
sup] By increasing intracellular cAMP level, phosphodiesterase
4 (PDE4) inhibitors are being developed as anti-inflammatory agents for the treatment of chronic inflammatory disorders such as asthma, chronic obstructive pulmonary disease, and psoriasis.
Learn How to Profile Phosphodiesterases
Using the AMP/GMP TR-FRET Assay:
Effects of sildenafil on the relaxation of human corpus cavemosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase
The availability of phosphodiesterase
type 5 inhibitors (PDE5i) has resulted in increasing numbers of patients seeking medical help for erectile function problems, but has also altered dramatically the medical management of ED (Hatzichristou and Pescatori, 2001; Lewis et al.
In estrogen-replete women, type-5 phosphodiesterase
inhibitors are thought to increase blood flow, engorgement, and lubrication to the genitalia, resulting in improved sensation and arousal.
Several alternative theories concerning the action of xanthines have been proposed in addition to phosphodiesterase
Food and Drug Administration (FDA) has ordered labeling changes for erectile-dysfunction (ED) medications known as phosphodiesterase
5 inhibitors to reflect a potential risk of sudden hearing loss associated with using the drugs.
Tokyo, Japan, June 9, 2006 - (JCN) - Tanabe Seiyaku and Maruho have jointly announced that they have entered into a licensing agreement for phosphodiesterase
4 (PDE4) inhibitor, a drug candidate for treating skin disease.
Serodiagnosis of louse-borne relapsing fever with glycerophosphodiester phosphodiesterase
(GIpQ) from Borrelia recurrentis.